Biomarkers of endocannabinoid system activation in severe obesity
about
Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axisAmygdala FAAH and anandamide: mediating protection and recovery from stressDevelopmental regulation of fear learning and anxiety behavior by endocannabinoids.FAAH genetic variation enhances fronto-amygdala function in mouse and human.Endocannabinoid signaling in the etiology and treatment of major depressive illness.Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and womenFrom Fertilisation to Implantation in Mammalian Pregnancy-Modulation of Early Human Reproduction by the Endocannabinoid System.A covering method for detecting genetic associations between rare variants and common phenotypes.Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructureRole of the tumor suppressor IQGAP2 in metabolic homeostasis: Possible link between diabetes and cancer.Endocannabinoids measurement in human saliva as potential biomarker of obesity.Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors.New insights on the role of the endocannabinoid system in the regulation of energy balance.Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient miceKrill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjectsAssociation of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesityCorticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety.Leptin levels are negatively correlated with 2-arachidonoylglycerol in the cerebrospinal fluid of patients with osteoarthritis.Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis.High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets385 C/A polymorphism of the fatty acid amide hydrolase gene is associated with metabolic syndrome in the Chinese Han population.Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS.Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adultsContributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic AdmixturePeripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation.The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.Neurobiological Interactions Between Stress and the Endocannabinoid System.Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Temporal changes in N-acylethanolamine content and metabolism throughout the peri-adolescent period.N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipidsNutritional properties of dietary omega-3-enriched phospholipids.Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnessesAnalytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices.Biomarkers in the field of obesity and its related comorbidities.Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?FAAH Gene Variation Moderates Stress Response and Symptom Severity in Patients with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence.The endocannabinoid system as a target for novel anxiolytic drugs.Identification of a Widespread Palmitoylethanolamide Contamination in Standard Laboratory Glassware.
P2860
Q26991850-8D23146A-B601-4F4F-9D78-29126C0A1EB4Q27026443-4C6D8E56-C9BB-4DD2-A015-C78FE3DAB071Q30366747-7E4AE2AB-95D5-4BCB-AE77-60830117088CQ30625337-5EDF485A-883B-46CA-925E-31E8ED611568Q30687668-3CD6792E-A662-4358-A1C5-3556B873497DQ33600484-AE2E225A-1B92-44C7-90AE-B1F503BDB554Q33664729-CDCE959B-A252-4A02-988D-108421CA56BCQ33728635-D7CC0E0D-3872-48EF-A67C-F0D8DDE39238Q34104954-F94A4C6C-CA6D-4FA6-9A42-21ECC31944CDQ34218516-39B946A8-657A-430A-8F26-425E017E88DEQ34364857-B87F28D6-B97A-4071-95FF-F2EA5FEC3B24Q34393055-16928448-E021-446A-81E1-CFBF84934C3AQ34494301-DD00ACA4-FADB-4860-AE88-C1C0B72322A1Q34608846-050A480C-BD0E-44F6-AE1F-DCADD408CA2DQ34623269-12DD4CF1-96F0-4649-8B50-A15492ECB6E9Q35053292-B4A39198-0ED5-4AA9-84E9-C3F2238B5560Q35108574-11D8B386-6432-4267-9494-787691051DF3Q35142902-78BE14FE-F33F-4B42-B824-C804E94E30E6Q35249407-E5A06CD1-6BB9-4680-ADC8-B553723886B7Q35271208-89605CF2-6DFD-47C6-A2C0-68F0C7F9947BQ35347646-2BB24123-7419-46DE-91D1-ED3682D66E2FQ35674194-EA978EBB-930C-477E-96CA-CC257D9DA2D3Q35747785-FA9AEACA-8E8D-48A3-BCF8-45A41C4C76CFQ35757921-FE63AAA9-4ECA-4C99-B1A4-15DEC9AF14EFQ35784024-D03A3B04-D1D3-4739-9F75-FB25054B7F4AQ35839405-AF65D024-7A2E-46B5-B265-7CDDA7115EA3Q35839912-5F29C7C2-CBA1-4750-8DD8-3E944CD4B230Q35925403-FFC7F187-26B6-4F3A-90F4-9BFA22737B66Q36366731-AEBD59FC-72CA-40FB-B64A-1051880248D8Q36373581-760E540E-B058-4BE3-8C7E-50A601FF2F73Q36434620-C0A83C80-5C07-4699-9E67-2A0B9BC97502Q37103635-952D4D55-C0D8-4A36-925E-02C6ACDBEF6DQ37105403-982FB57B-566C-4DE8-9608-692973B0BBD9Q37279826-9B0E0575-6567-4FA3-ABF6-EB8D4AC68F57Q38161854-4769F518-88F5-43AC-AF20-332FA746549BQ38183431-2F6CBA00-4CB8-4BC9-B77D-666A5234894AQ38707482-4D398A7F-8178-47BD-94CE-1D70B3782C93Q38809372-0254FB82-D1F3-4F52-A7B6-1888885B5F60Q39257178-E49549D7-5253-4161-8E5F-E20F99A6C0D6Q41016991-F97C07D0-C898-472D-8AC8-D86BC9418B8D
P2860
Biomarkers of endocannabinoid system activation in severe obesity
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biomarkers of endocannabinoid system activation in severe obesity
@ast
Biomarkers of endocannabinoid system activation in severe obesity
@en
Biomarkers of endocannabinoid system activation in severe obesity.
@nl
type
label
Biomarkers of endocannabinoid system activation in severe obesity
@ast
Biomarkers of endocannabinoid system activation in severe obesity
@en
Biomarkers of endocannabinoid system activation in severe obesity.
@nl
prefLabel
Biomarkers of endocannabinoid system activation in severe obesity
@ast
Biomarkers of endocannabinoid system activation in severe obesity
@en
Biomarkers of endocannabinoid system activation in severe obesity.
@nl
P2093
P2860
P921
P1433
P1476
Biomarkers of endocannabinoid system activation in severe obesity
@en
P2093
Gabriel M Simon
Jack C Sipe
Jill Waalen
Sarah Murray
T Michael Scott
P2860
P356
10.1371/JOURNAL.PONE.0008792
P407
P577
2010-01-20T00:00:00Z